NASDAQ:APTO

Aptose Biosciences - APTO Stock Forecast, Price & News

$0.59

0.00 (0.00%)

(As of 10/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.58
▼
$0.60
50-Day Range: $0.54
▼
$0.87
52-Week Range: $0.54
▼
$2.78

Volume: 88,956 shs
Average Volume: 320,448 shs
Market Capitalization: $54.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.67

Aptose Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,368.9% Upside
$8.67 Price Target
Short Interest: Healthy
0.27% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$6,800 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.48) to ($0.51) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

355th out of 1,075 stocks

Biological Products, Except Diagnostic Industry

58th out of 170 stocks

3.5

Analyst's Opinion

Consensus Rating
Aptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.67, Aptose Biosciences has a forecasted upside of 1,368.9% from its current price of $0.59.
Amount of Analyst Coverage
Aptose Biosciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.27% of the outstanding shares of Aptose Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Aptose Biosciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aptose Biosciences has recently increased by 18.70%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aptose Biosciences does not currently pay a dividend.
Dividend Growth
Aptose Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APTO.

3.7

News and Social Media Coverage

News Sentiment
Aptose Biosciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aptose Biosciences this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for APTO on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
MarketBeat Follows
2 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptose Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,800.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
10.94% of the stock of Aptose Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 27.16% of the stock of Aptose Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aptose Biosciences are expected to decrease in the coming year, from ($0.48) to ($0.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aptose Biosciences is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aptose Biosciences is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aptose Biosciences has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aptose Biosciences (NASDAQ:APTO) Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APTO Stock News Headlines

October 3, 2022 | americanbankingnews.com

Aptose Biosciences Inc. (NASDAQ:APTO) Sees Significant Increase in Short Interest

September 29, 2022 | finance.yahoo.com

Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

September 29, 2022 | americanbankingnews.com

Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

September 20, 2022 | finance.yahoo.com

Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication

September 19, 2022 | finance.yahoo.com

Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe

September 14, 2022 | finance.yahoo.com

Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference

September 13, 2022 | finance.yahoo.com

Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal

September 12, 2022 | reuters.com

Aptose Biosciences Inc

September 12, 2022 | finance.yahoo.com

Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability

August 31, 2022 | benzinga.com

H.C. Wainwright 24th Annual Global Investment Conference

August 30, 2022 | finance.yahoo.com

Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 2, 2022 | msn.com

Aptose Biosciences: Q2 Earnings Insights

August 2, 2022 | finance.yahoo.com

Aptose Reports Results for the Second Quarter 2022

July 27, 2022 | finance.yahoo.com

Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

July 19, 2022 | seekingalpha.com

Aptose Biosciences Continues To Drift Without Thesis-Changing Data

June 27, 2022 | seekingalpha.com

Aptose names new CFO

June 27, 2022 | markets.businessinsider.com

Aptose Biosciences Appoints Fletcher Payne As CFO

June 2, 2022 | finance.yahoo.com

CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

June 2, 2022 | finance.yahoo.com

Aptose Presents Highlights from Corporate Update and KOL Event

May 25, 2022 | finance.yahoo.com

Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd

May 12, 2022 | finance.yahoo.com

Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

May 8, 2022 | seekingalpha.com

Aptose Biosciences Q1 2022 Earnings Preview

May 4, 2022 | marketwatch.com

Aptose Gets FDA Fast-Track Designation for HM43239 >APTO

May 4, 2022 | seekingalpha.com

Aptose stock rises as HM43239 gets FDA fast track status to treat blood cancer subtype

May 2, 2022 | finance.yahoo.com

Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APTO Company Calendar

Last Earnings: 8/02/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/10/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APTO
CUSIP: N/A
CIK: 882361
Web: www.aptose.com
Phone: 858-926-2730
Fax: 905-234-2120
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.67
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +1,368.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -81.36%
Return on Assets: -72.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.89
Quick Ratio: 6.89

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.81 per share
Price / Book: 0.73

Miscellaneous

Outstanding Shares: 92,295,000
Free Float: 82,198,000
Market Cap: $54.45 million
Optionable: Optionable
Beta: 1.54

Key Executives

Dr. William G. Rice Ph.D. (Age 59)
Chairman, Pres & CEO

Mr. Gregory K. Chow CPA (Age 45)
MBA, BA, Sr. VP, CFO & Principal Accounting Officer

Mr. Ernest Kitt B.S.
M.S, VP of Devel. & Technical Operations

Dr. Stephen B. Howell (Age 73)
Chief Medical Officer

Mr. Peter Murray
Director of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APTO Stock - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APTO shares.
View APTO analyst ratings or view top-rated stocks.
What is Aptose Biosciences' stock price forecast for 2022?: 3 Wall Street research analysts have issued twelve-month target prices for Aptose Biosciences' stock. Their APTO share price forecasts range from $6.00 to $12.00. On average, they anticipate the company's stock price to reach $8.67 in the next year. This suggests a possible upside of 1,368.9% from the stock's current price.
View analysts price targets for APTO or view top-rated stocks among Wall Street analysts.
How have APTO shares performed in 2022?: Aptose Biosciences' stock was trading at $1.35 at the beginning of 2022. Since then, APTO shares have decreased by 56.3% and is now trading at $0.59.
View the best growth stocks for 2022 here.
When is Aptose Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our APTO earnings forecast.
How were Aptose Biosciences' earnings last quarter?: Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings data on Tuesday, August, 2nd. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?: 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.
What other stocks do shareholders of Aptose Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).
What is Aptose Biosciences' stock symbol?: Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."
How do I buy shares of Aptose Biosciences?: Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aptose Biosciences' stock price today?: One share of APTO stock can currently be purchased for approximately $0.59.
How much money does Aptose Biosciences make?: Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $54.45 million. The biotechnology company earns $-65,350,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.
How can I contact Aptose Biosciences?: Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120.

This page (NASDAQ:APTO) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aptose Biosciences - APTO Stock Forecast, Price & News

Aptose Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows